Re:Covid: US backs waiver on vaccine intellectual property
by janekm on Thursday May 06, 2021 @06:59AM
(#27061430)
Simple, the Indian vaccine factories already have licenses to produce these vaccines but are struggling to scale up production: https://www.bbc.co.uk/news/world-asia-india-55571793 (in part because they can't get some of the supplies needed, which maybe could be helped if the patents for those are also waived and other factories can help to make those...)
Re:Covid: US backs waiver on vaccine intellectual property
by tobessebot on Thursday May 06, 2021 @08:53AM
(#27062455)
https://blogs.sciencemag.org/pipeline/archives/2021/02/02/my...
This is about mRNA vaccines, but similar things exist for viral vector vaccines as well. Technology transfer, bioreactor bags, fill-finish capacity, all of these things are bottlenecked till next year basically.
Why not? I’m not hearing a clear argument or evidence to support that withholding the patent recipe wouldn’t save millions of lives?
India now has a very high number of cases. As it stands now, your argument just sounds to me like:
“yes human lives, but... profit“.
Please could you elaborate on your argument and/or provide examples of what you’re describing happening in other cases?